A Study of JNJ-64281802 in Healthy Adult Participants

NCT05201937 ↗

Phase 1 Completed 33 enrolled Janssen Research & Development, LLC

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to assess the pharmacokinetics (PK) of JNJ-64281802 in healthy participants when administered in different multiple dose regimens and as different dose strengths.

Timeline

Start: 2022-02-23
Primary completion: 2022-12-11
Completion: 2022-12-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	mosnodenvir	Small molecule	—	Oral

Indications

No indication recorded.